文献速递免疫规划传染病防控与疫情报告

两种新冠基础疫苗系列免疫原性的持续差异受加强mRNA疫苗接种和突破性感染调节

Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection.
PubMed 文献 · Vaccine · 2024-05-09

韩国10家三级医院前瞻性队列纳入235名医护人员,比较ChAdOx1/ChAdOx1/BNT162b2(CCB组,166人)与BNT162b2/BNT162b2/BNT162b2(BBB组,69人)的免疫原性。基础系列后BBB组Sab、IGRA及多种细胞因子升高显著高于CCB组;第三剂BNT162b2加强后1个月CCB组Sab水平与BBB组相当;无突破性感染6个月后两组均下降;发生BA.1/2突破性感染后BBB组Sab升高显著高于CCB组。两种基础系列诱导的免疫原性差异持续存在,受后续加强疫苗和突破性感染调节。

要点

  • 基础系列后BBB组Sab、IGRA及多种细胞因子升高显著高于CCB组(均P<0.05)。
  • 第三剂加强后1个月CCB组Sab水平与BBB组相当,无突破性感染6个月后两组均下降。
  • BA.1/2突破性感染后BBB组Sab升高显著高于CCB组(P<0.001)。

核心结论

  • 两种基础疫苗系列诱导的免疫原性差异持续存在,并受后续加强疫苗接种和突破性感染调节。

研究设计与样本

  • 2021年3月至2022年9月在韩国10家三级医院开展的前瞻性队列研究,纳入235名已接种两剂ChAdOx1或BNT162b2基础系列并接受第三剂BNT162b2加强的医护人员,按疫苗系列分为CCB组166人和BBB组69人。

主要发现

  • 基础疫苗系列后,BBB组Sab水平、IGRA反应及多种细胞因子(CCL2/MCP-1、CCL3/MIP-1α、CCL4/MIP-1β、IL-1ra、IFN-γ、IL-2、IL-4、IL-10)升高显著高于CCB组(均P<0.05)。
  • 第三剂BNT162b2加强后1个月,CCB组Sab水平与BBB组相当,无突破性感染6个月后两组水平均下降。
  • 第三剂加强后发生BA.1/2突破性感染者中,BBB组Sab水平升高显著高于CCB组(P<0.001)。
  • 第三剂加强后,BBB组对Spike1和Spike2蛋白的IGRA反应均显著强于CCB组;突破性感染后仅Spike2反应更高(P=0.007)。
  • 突破性感染后BBB组T细胞细胞因子(IL-2、IL-4、IL-17A)增强强于CCB组(P<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The long-term impact of initial immunogenicity induced by different primary COVID-19 vaccine series remains unclear. METHODS: A prospective cohort study was conducted at 10 tertiary hospitals in Korea from March 2021 to September 2022. Immunogenicity assessments included anti-spike protein antibody (Sab), SARS-CoV-2-specific interferon-gamma releasing assay (IGRA), and multiplex cytokine assays for spike protein-stimulated plasma. Spike proteins derived from wild-type SARS-CoV-2 and alpha variant (Spike1) and beta and gamma variant (Spike2) were utilized. RESULTS: A total of 235 healthcare workers who had received a two-dose primary vaccine series of either ChAdOx1 or BNT162b2, followed by a third booster dose of BNT162b2 (166 in the ChAdOx1/ChAdOx1/BNT162b2 (CCB) group and 69 in the BNT162b2/BNT162b2/BNT162b2 (BBB) group, based on the vaccine series) were included. Following the primary vaccine series, the BBB group exhibited significantly higher increases in Sab levels, IGRA responses, and multiple cytokines (CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β, interleukin (IL)-1ra, IFN-γ, IL-2, IL-4, and IL-10) compared to the CCB group (all P < 0.05). One month after the third BNT162b2 booster, the CCB group showed Sab levels comparable to those of the BBB group, and both groups exhibited lower levels after six months without breakthrough infections (BIs). However, among those who experienced BA.1/2 BIs after the third booster, Sab levels increased significantly more in the BBB group than in the CCB group (P < 0.001). IGRA responses to both Spike1 and Spike2 proteins were significantly stronger in the BBB group than the CCB group after the third booster, while only the Spike2 response were higher after BIs (P = 0.007). The BBB group exhibited stronger enhancement of T-cell cytokines (IL-2, IL-4, and IL-17A) after BIs than in the CCB group (P < 0.05). CONCLUSION: Differences in immunogenicity induced by the two primary vaccine series persisted, modulated by subsequent booster vaccinations and BIs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lee KY, Song KH, Lee KH, et al. Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection. Vaccine. 2024. PMID: 38729909. doi:10.1016/j.vaccine.2024.05.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。